Showing search results for "Schröder FH"
, Screening, Men, Antigen,
, Risk, Disease, Patients, Mortality, Pca, Biopsy, Treatment, Cancers, Incidence, Death, Reductase, Lead, Life
Information and abstracts for author publications
Baseline prostate-specific antigen testing at a young age.
Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.
Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly.
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.
European journal of cancer (Oxford, England : 1990)
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
International journal of cancer. Journal international du cancer
Identifying and characterizing "escapes"-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam).
Nature reviews. Urology
Risk factors: increased risk of suicide after prostate cancer diagnosis.
Can the prostate risk calculator based on Western population be applied to Asian population?
Acta oncologica (Stockholm, Sweden)
Screening for prostate cancer---the controversy continues, but can it be resolved?
Prostate cancer around the world. An overview.
Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
Prostate cancer: a serious disease suitable for prevention.
Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.
Landmarks in prostate cancer screening.
Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
A Syngeneic Mouse B-Cell Lymph…
Use of Principal Components for Scaling Up Topographic Models to Map Soil Redistribution and Soil Organic Carbon
Use of Principal Components fo…
Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
Amplification of Near Full-len…
Assays for Studying the Role of Vitronectin in Bacterial Adhesion and Serum Resistance
Assays for Studying the Role o…
Analyzing Protein Architectures and Protein-Ligand Complexes by Integrative Structural Mass Spectrometry
Analyzing Protein Architecture…
Small-Scale Colorimetric Assays of Intracellular Lactate and Pyruvate in the Nematode
Small-Scale Colorimetric Assay…
Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
Efficient Purification and LC-…
Determination of Reproductive Competence by Confirming Pubertal Onset and Performing a Fertility Assay in Mice and Rats
Determination of Reproductive …
Fabricating a Kidney Cortex Extracellular Matrix-Derived Hydrogel
Fabricating a Kidney Cortex Ex…
Stress-Enhanced Fear Learning, a Robust Rodent Model of Post-Traumatic Stress Disorder
Stress-Enhanced Fear Learning,…
JoVE subscription required to view articles
Related JoVE Videos